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Abstract
Background: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are systemic inflammatory
disorders that include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), Churg-Strauss
syndrome and renal limited vasculitis (RLV). Extracellular high-mobility group box 1 (HMGB1) acts as an alarmin and
has been shown to be a biomarker of disease activity as well as an autoantigen in systemic lupus erythematosus
(SLE) and, possibly, in AAV. This study aims to assess antibodies against HMGB1 and HMGB1 levels as biomarkers
for AAV disease activity and predictors of relapsing disease.
Methods: AAV patients with active disease and healthy controls (HC) were evaluated for anti-HMGB1 antibodies
while serum HMGB1 levels were measured longitudinally in AAV patients at presentation, during remission, prior to
and at relapses.
Results: HMGB1 levels were similar between AAV patients at presentation (n = 52) and HC (n = 35) (2.64 ± 1.80
ng/ml vs. 2.39 ± 1.09 ng/ml; P = 0.422) and no difference regarding HMGB1 levels could be found among AAV
disease subsets (GPA: 2.66 ± 1.83 ng/ml vs. MPA: 3.11 ± 1.91 ng/ml vs. RLV: 1.92 ± 1.48 ng/ml; P = 0.369). AAV
patients with renal involvement had lower HMGB1 levels than patients without renal involvement at presentation
(2.35 ± 1.48 ng/ml vs. 3.52 ± 2.41 ng/ml; P = 0.042). A negative correlation was observed between HMGB1 levels
and 24-hour proteinuria (r = -0.361, P = 0.028). Forty-nine AAV patients were evaluated for HMGB1 levels during
follow-up and no differences were observed between relapsing and nonrelapsing patients (P = 0.350). No
significant increase in HMGB1 levels was observed prior to a relapse compared with the remission period and
changes in HMGB1 levels were not associated with an increased risk for relapse in AAV. Positivity for anti-HMGB1
antibodies was low in patients with active AAV (three out of 24 patients).
Conclusions: Serum HMGB1 levels at presentation are not increased and are lower in patients with renal
involvement. Relapses are not preceded or accompanied by significant rises in HMGB1 levels and changes in
HMGB1 levels are not related to ensuing relapses. Anti-HMGB1 antibodies are present in only a few patients in
AAV. In contrast to SLE, HMGB1 is not a useful biomarker in AAV.
Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitides (AAV) are primary systemic vasculitides
affecting small and medium-sized vessels, and are asso-
ciated with ANCA against proteinase 3 (PR3) and mye-
loperoxidase. AAV include granulomatosis with
polyangiitis (GPA), microscopic polyangiitis (MPA),
Churg-Strauss syndrome, and isolated pauci-immune
necrotizing crescentic glomerulonephritis also desig-
nated as renal limited vasculitis (RLV) [1,2]. Disease
relapses are common in AAV and occur in up to 60% of
patients, especially in patients with GPA and PR3
ANCA [3-7]. Risk factors for relapses in AAV include
the persistence of PR3 ANCA after induction of remis-
sion, upper and lower airway involvement, cardiovas-
cular involvement, and chronic nasal carriage of
Staphylococcus aureus, particularly strains that express
the toxic shock syndrome toxin-1 superantigen gene
[3,5,6,8]. A recent meta-analysis showed that the rise in
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ANCA titers or their persistence during remission is
only modestly associated with an increased risk of
relapses in AAV patients [9]. There is thus an unmet
need for biomarkers predicting which AAV patient is
prone to relapse.
High-mobility group box-1 (HMGB1) is a nuclear pro-
tein that binds DNA and modulates chromosomal archi-
tecture. Once released into the extracellular space, after
cell death or upon activation, HMGB1 acts as a danger-
associated molecular pattern or as an alarmin and sti-
mulates inflammatory and immunological activities that
include cytokine production, chemotaxis, cell prolifera-
tion, angiogenesis and cell differentiation. HMGB1 has
to bind to the receptor for advanced glycation end-
products (RAGE) and toll-like receptor (TLR)-2, TLR-4
and TLR-9 in order to exert its actions [10,11].
In systemic lupus erythematosus (SLE), serum
HMGB1 has been shown to be a biomarker of disease
activity, especially in patients with lupus nephritis.
Moreover, patients with active lupus nephritis present
higher HMGB1 levels in urine compared with SLE
patients without active nephritis and with controls
[12-14]. Furthermore, levels of antibodies to HMGB1
are higher in patients with active SLE than in patients
with quiescent disease and in controls [13]. In AAV, a
cross-sectional study showed increased serum levels of
HMGB1 in patients with active GPA [15]. In addition,
one study found an association with granulomatous
manifestations and another with biopsy-proven renal
involvement [16,17].
Until now, HMGB1 levels have not been evaluated
longitudinally as a biomarker of disease activity or as a
predictor of ensuing relapses in patients with AAV. The
aims of this study were to evaluate whether serial levels
of HMGB1 reflect changes in disease activity and/or
predict the occurrence of relapses, and to analyze
whether AAV patients have antibodies to HMGB1.
Materials and methods
Patients
Patients on follow-up at the University Medical Center
Groningen with a diagnosis of AAV, including GPA,
MPA, and RLV, were eligible for the study. Patients had
a clinical diagnosis of GPA or MPA according to the
European Medicines Agency algorithm [18]. Patients
with isolated renal involvement, ANCA positivity and
biopsy-proven pauci immune necrotizing glomerulone-
phritis were classified as RLV. ANCA tests were per-
formed in all patients by indirect immunofluorescence
using ethanol-fixed neutrophils, while ANCA specificity
for PR3 or myeloperoxidase was assessed by enzyme-
linked immunosorbent assay (ELISA). To assess whether
HMGB1 levels are increased in active disease, 52 AAV
patients were included at presentation; characteristics
are presented in Table 1. Additionally, 49 out of 52
AAV patients with sufficient follow-up data were
included in a longitudinal analysis and were evaluated
during a mean period of 54.4 ± 17.6 months. Thirty-five
age-matched and sex-matched healthy controls (HC)
were evaluated for HMGB1 levels in the study as well.
All patients and HC gave informed consent. The study
was conducted according to the ethical guidelines of the
University Medical Center Groningen, approved by the
Table 1 Baseline features at presentation and therapy in
52 patients with antineutrophil cytoplasmic antibodies-
associated vasculitis
Variable Result
Diagnosis
Granulomatosis with polyangiitis 33 (63.5)
Microscopic polyangiitis 11 (21.2)
Renal limited vasculitis 8 (15.4)
ANCA
Proteinase 3 ANCA 30 (57.7)
Myeloperoxidase ANCA 22 (42.3)
Disease activity
Median BVAS 15.0 (12.0 to 23.5)
Median C-reactive protein level (mg/l) 37.0 (11.5 to 81.5)
Disease manifestations
Renal involvement 39 (75.0)
Systemic manifestations 32 (61.5)
Ear, nose and throat involvement 28 (53.8)
Pulmonary involvement 22 (42.3)
Arthritis/joint pain 18 (34.6)
Peripheral neuropathy 15 (28.8)
Eye involvement 13 (25.0)
Cutaneous vasculitis 12 (23.1)
Pulmonary involvement
Pulmonary nodules and/or infiltrates 12 (23.0)
Alveolar hemorrhage 6 (11.5)
Pleural effusion 2 (3.8)
Endobronchial lesion 1 (1.9)
Renal-related variables
Median 24-hour proteinuria (g) 0.90 (0.55 to 1.60)
Hematuria (>10 RBC/HPF) 39 (75.0)
Median creatinine (μmol/l) 137.0 (80.0 to 350.0)
Mean creatinine clearance (ml/minute/1.73 m2) 65.7 ± 41.7
Dialysis dependent 8 (15.4)
Actual therapy
Patients without treatment 27 (51.9)
Prednisolone and cyclophosphamide 13 (25.0)
Prednisolone only 7 (13.5)
Plasmapheresis 6 (11.5)
Mean number of plasmapheresis sessions 9.33 ± 1.50
Methotrexate 1 (1.9)
Data presented as n (%), median (interquartile range) or mean ± standard
deviation. ANCA, antineutrophil cytoplasmic antibodies; BVAS, Birmingham
Vasculitis Activity Score; HPF, high-power field; RBC, red blood cells.
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ethical committee of the University Medical Center Gro-
ningen, and in accord with the Declaration of Helsinki.
AAV patients and HC were matched for age (58.8 ±
14.0 vs. 55.7 ± 11.7 years; P = 0.277) and gender (44.2%
vs. 51.4% females; P = 0.510). Throughout the study,
AAV patients were evaluated for HMGB1 levels, disease
activity using the third version of the Birmingham Vas-
culitis Activity Score (BVAS) [19], ANCA status, C-reac-
tive protein (CRP) levels, and therapy. Complete
remission was defined as a BVAS of 0 in combination
with a normal serum CRP level (<10 mg/l). Relapse was
defined as the need to restart or intensify immunosup-
pressive therapy due to biopsy-proven or clinically sus-
pected vasculitic disease activity. Anti-HMGB1
antibodies were tested in a randomly selected sample of
AAV patients with active disease and data were com-
pared with those in HC. In the longitudinal analysis,
AAV patients were evaluated for HMGB1 serum levels
at presentation, and twice during the remission period,
namely at 3 months (interquartile range 3 to 6) and 11
months (interquartile range 6 to 12) after presentation.
For relapsing AAV patients, HMGB1 levels were mea-
sured 2 months (interquartile range 1 to 3) prior to
each relapse and at the moment of relapse. Relapsing
and nonrelapsing AAV patients were compared regard-
ing HMGB1 levels at baseline and during the remission
period.
ELISA for serum HMGB1
HMGB1 levels were assessed in AAV patients and HC
using a commercial ELISA kit according to the manu-
facturer’s instructions (Shino Test; Sagamihara, Kana-
gawa, Japan). Results of serum HMGB1 levels are
expressed in nanograms per milliliter.
ELISA for anti-HMGB1 antibodies
Anti-HMGB1 antibodies were tested in 24 AAV patients
with active disease and 18 HC using an in house-devel-
oped ELISA described previously [13]. Sera from two
patients with active SLE and high titers of anti-HMGB1
antibodies were used as positive controls. Briefly, Maxi-
sorp polystyrene 96-well plates were coated with 50 μl/
well recombinant HMGB1 (R&D Systems, Abingdon,
UK) at 1 μg/ml in phosphate-buffered saline and incu-
bated overnight at 4°C. Plates were then blocked with 5%
bovine serum albumin in phosphate-buffered saline for 2
hours. Serum samples, diluted 1:50 in incubation buffer,
were added to the plate (100 μl/well) and incubated for 2
hours at room temperature. After five washes, 100 μl
horseradish peroxidase-conjugated goat anti-human
IgG (SouthernBiotech, Birmingham, AL, USA) diluted
1:3,000 was added to each well and incubated for 1 hour
at room temperature. After washing, bound antibodies
were detected using 3,3’,5,5’-tetramethylbenzidine
dihydrochloride. The reaction was stopped with 2 M
sulfuric acid and the absorbance was measured at
450 nm using a microplate spectrophotometer (Vmax;
Molecular Devices, Sunnyvale, CA, USA). Results are
expressed as optical density (OD) and anti-HMGB1 anti-
bodies were considered positive if OD values were above
the cutoff level of 0.435 obtained from the mean plus
twice the standard deviation in 18 HC.
Statistical analysis
Statistical analysis was performed using SPSS software
version 20.0 and graphs were built using Graph Pad
Prism version 3.02. Categorical variables were presented
as the total number and percentage whereas continuous
data were presented as the mean ± standard deviation
when variables were normally distributed or as the med-
ian and interquartile range in case of non-normal distri-
bution. Comparison between groups was performed
using the chi-square test or Fisher’s exact test for cate-
gorical variables and Student’s t test or the Mann-Whit-
ney U test for continuous data. One-way analysis of
variance test was used for comparisons between three or
more groups for numerical variables, and post-hoc analy-
sis was performed with Dunnet’s or Tukey’s tests. Cor-
relation between numerical data was calculated using
Spearman’s or Pearson’s correlation coefficient when
appropriate. Fluctuations in HMGB1 levels during fol-
low-up in AAV patients were evaluated by Friedman’s
test and in cases of significance the Wilcoxon rank-sum
test was used. Comparison between relapsing and non-
relapsing AAV patients regarding HMGB1 levels during
follow-up was performed by generalized estimating
equations. Cox proportional hazard models were built to
analyze whether changes in HMGB1 levels were related
to time of first relapse in AAV patients. Results are
expressed as the hazard ratio and 95% confidence inter-
val. The significant level accepted was 5% (P < 0.05).
Results
Baseline features of AAV patients
Characteristics of the 52 patients included in the study
are presented in Table 1. All AAV patients were positive
for anti-PR3 ANCA (n = 30) or anti-myeloperoxidase
ANCA (n = 22) at presentation. Eight GPA patients
(15%) had localized disease restricted to the upper and/
or lower respiratory tract, eyes and/or ears, whereas
active renal involvement was the most frequent disease
manifestation at baseline. Most AAV patients (52%)
were not on treatment at baseline evaluation, while
among treated patients the combination of prednisolone
and oral cyclophosphamide was most commonly pre-
scribed (Table 1). In the patients already on immuno-
suppressive therapy, the median duration prior to
baseline evaluation was 3.0 weeks (interquartile range
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1.0 to 4.0). In this subgroup the median daily predniso-
lone dose was 60 mg while the median daily dose of
oral cyclophosphamide was 150 mg. Although those
patients were already under therapy at baseline evalua-
tion, no difference regarding median BVAS could be
found between treated and untreated patients (14.0
(12.0 to 23.0) vs. 15.0 (12.0 to 26.0); P = 0.491).
HMGB1 levels at baseline
Mean HMGB1 levels were similar between AAV
patients and HC (2.64 ± 1.80 ng/ml vs. 2.39 ± 1.09 ng/
ml; P = 0.422) and no significant differences were found
regarding mean HMGB1 levels among AAV disease sub-
sets (GPA: 2.66 ± 1.83 ng/ml vs. MPA: 3.11 ± 1.91 ng/
ml vs. RLV: 1.92 ± 1.48 ng/ml; P = 0.369). Although not
significant, HMGB1 levels were higher in GPA patients
with localized disease in comparison with those present-
ing generalized disease (3.14 (1.87 to 3.78) ng/ml vs.
1.84 (1.30 to 3.36) ng/ml; P = 0.240) as well as in AAV
patients with pulmonary nodules and/or infiltrates com-
pared with those presenting alveolar hemorrhage (3.60 ±
1.99 ng/ml vs. 2.09 ± 1.18 ng/ml; P = 0.107), but these
differences did not reach statistical significance. Patients
who were already under treatment for AAV at baseline
had similar mean HMGB1 levels in comparison with
those patients without immunosuppressive therapy (2.52
± 1.58 ng/ml vs. 2.75 ± 2.01 ng/ml; P = 0.651) while
lower HMGB1 levels were found in AAV patients who
underwent sessions of plasmapheresis and/or dialysis
prior to baseline evaluation of HMGB1 than in AAV
patients without these therapies (1.84 ng/ml (1.55 to
2.79) vs. 2.63 ng/ml (1.22 to 3.88); P = 0.388), but this
difference was not significant. A positive but weak cor-
relation was found between serum HMGB1 and CRP
levels (r = 0.341; P = 0.039) (Figure 1), while no correla-
tion was found between serum HMGB1 levels and
BVAS (r = -0.019; P = 0.896), cytoplasmic ANCA titers
(r = -0.208; P = 0.271) or perinuclear ANCA titers (r =
0.054; P = 0.813) at presentation.
Patients without renal involvement (n = 13) had
increased levels of HMGB1 compared with HC (P =
0.023). In contrast, HMBG1 levels in patients with renal
involvement (n = 39) were no different from those in
HC (P = 0.733) (Figure 2). No significant difference in
mean HMGB1 levels was found between patients with
renal involvement who presented granulomatous mani-
festations in comparison with those without associated
granulomatous manifestations (2.34 ± 1.53 ng/ml (n =
22) vs. 2.37 ± 1.46 ng/ml (n = 17); P = 0.826). A nega-
tive correlation was observed between serum HMGB1
levels and 24-hour proteinuria (r = -0.361, P = 0.028)
whereas no correlation was found between serum
HMGB1 levels and creatinine clearance in AAV patients
with renal involvement (r = 0.330; P = 0.144).
Longitudinal analysis of HMGB1 levels and relapses
To verify whether HMGB1 levels follow disease activity
in AAV, HMGB1 levels were measured at presentation
and during the remission period. A significant decrease
in median HMGB1 levels (2.35 ng/ml (1.48 to 3.15) vs.
1.69 ng/ml (0.88 to 2.73); P = 0.006) was observed at
the moment remission had been induced in comparison
with baseline but then levels increased significantly
Figure 1 Correlation between serum HMGB1 and C-reactive
protein levels at presentation in AAV patients. A significant
positive correlation was found between serum high-mobility group
box 1 (HMGB1) and C-reactive protein (CRP) levels in antineutrophil
cytoplasmic antibodies-associated vasculitis (AAV) patients at
presentation (r = 0.341; P = 0.039).
Figure 2 Baseline HMGB1 levels in AAV patients with renal
involvement, without renal involvement and controls. High-
mobility group box 1 (HMGB1) levels at presentation in
antineutrophil cytoplasmic antibodies-associated vasculitis (AAV)
patients with renal involvement and without renal involvement and
in healthy controls (HC) (2.35 ± 1.48 ng/ml vs. 3.52 ± 2.41 ng/ml vs.
2.39 ± 1.09 ng/ml; P = 0.046). Using Dunnett’s post-hoc test,
nonrenal AAV patients had higher HMGB1 levels when compared
with HC (P = 0.023) whereas no difference was found between
patients with renal involvement and HC (P = 0.733).
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again during ongoing remission (1.69 ng/ml (0.88 to
2.73) vs. 2.21 ng/ml (1.42 to 3.68); P = 0.004) (Figure 3
and Table 2). During follow-up, at least one disease
relapse was observed in 17 AAV patients (34.7%), of
whom six patients suffered from two relapses. GPA was
the most frequent AAV subset among relapsing patients
(82%). No significant differences regarding HMGB1
levels were observed between relapsing and nonrelapsing
AAV patients during follow-up (relapsing: 2.18 ng/ml
(1.49 to 3.15), 1.67 ng/ml (0.90 to 3.29) and 2.36 (1.33
to 2.75) vs. nonrelapsing: 1.97 ng/ml (1.10 to 3.72), 1.72
ng/ml (0.84 to 2.46) and 2.17 (1.44 to 3.97) at presenta-
tion and at remission 3 and 11 months after presenta-
tion, respectively; P = 0.350) (Figure 4).
Aiming to evaluate whether an increase in HMGB1
levels during the remission period could indicate an
increased risk of relapse, AAV patients were also evalu-
ated prior to a relapse. However, no significant increase
in serum HMGB1 levels could be observed prior to a
relapse in comparison with HMGB1 levels during the
remission period. Moreover, serum HMGB1 levels prior
to a relapse were similar in comparison with HMGB1
levels during the relapses (Figure 3 and Table 2). Serum
HMGB1 levels at different time points were not
associated with an increased risk of relapse of AAV
while fluctuations of serum HMGB1 levels between
remission and prior to the first relapse were not asso-
ciated with an increased risk for relapses (Table 3).
Antibodies against HMGB1
Median OD values for anti-HMGB1 antibodies were
similar between AAV patients with active disease and
HC (0.175 (0.110 to 0.293) vs. 0.254 (0.177 to 0.297);
P = 0.151). Anti-HMGB1 antibodies were positive in
only three out of 24 patients (12.5%) with active AAV,
in a median titer (OD: 0.465; range: 0.442 to 0.556)
lower than in the two SLE patients included as positive
controls (0.592 and 0.659, respectively). Albeit not sig-
nificant, the AAV patients positive for anti-HMGB1
antibodies had a higher BVAS in comparison with those
without anti-HMGB1 antibodies (26.0 (21.5 to 30.5) vs.
12.0 (6.0 to 19.0); P = 0.060).
Discussion
In this study, we evaluated serum HMGB1 levels as a
biomarker of disease activity in AAV and investigated
anti-HMGB1 antibodies in AAV patients with active dis-
ease. We observed that even though a significant corre-
lation was found between HMGB1 and CRP levels at
presentation, only AAV patients without active renal
disease had significantly higher serum HMGB1 levels
than HC. Serum HMGB1 levels decreased significantly
in a median of 3 months after presentation but then
returned to levels similar to those found at baseline and
no significant fluctuation was seen over time in AAV
patients, not prior to or during disease relapses. Only a
minority of AAV patients with active disease develop
anti-HMGB1 antibodies.
Anti-HMGB1 antibodies have been described in sera
of patients with septic shock, polymyositis, dermatomyo-
sitis and in active SLE [13,20]. In critically ill patients
with septic shock, anti-HMGB1 antibodies were asso-
ciated with a better prognosis and increased survival
[21]. In patients with SLE, anti-HMGB1 antibodies were
positively correlated with disease activity and anti-dou-
ble-stranded DNA titers and were negatively correlated
with serum complement levels [13,20]. In this study,
only a small minority of AAV patients were positive for
anti-HMGB1 antibodies. Moreover, no significant asso-
ciation between anti-HMGB1 antibodies and BVAS
score could be observed. A previous study also failed to
demonstrate anti-HMGB1 antibodies in 22 patients with
AAV and active renal involvement [22].
The technique used to measure serum HMGB1 levels
is a relevant issue because serum HMGB1 levels are
usually five times higher when a western blot technique
is used in comparison with ELISA, although both assays
correlate well [23]. The binding of HMGB1 to different
Figure 3 Longitudinal fluctuation of HMGB1 levels in different
phases of the disease in AAV patients. High-mobility group box
1 (HMGB1) levels decrease significantly from presentation to when
remission was induced (P = 0.006) but returned to levels similar to
baseline at ongoing remission. No significant changes in HMGB1
levels were observed prior to or during disease relapses in
antineutrophil cytoplasmic antibodies-associated vasculitis (AAV)
patients. Box and whisker plots indicate the 25 to 75% range
(boxes), the 5 to 95% range (error bars), and the median value
(horizontal lines); dots represent outliers.
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serum/plasma molecules, especially IgG1, interferes with
its detection by ELISA systems, which is considered the
main reason for this discrepancy [24]. Moreover, the
depletion of IgG from the sera of SLE patients lowered
serum HMGB1 levels detected by ELISA, indicating that
this interference might in part be due to anti-HMGB1
antibodies in SLE [13]. We therefore firstly tested anti-
HMGB1 antibodies in AAV patients before choosing the
technique to measure serum HMGB1. Since only a few
AAV patients presented anti-HMGB1 antibodies, the
ELISA technique was used to measure serum HMGB1
in the present study. Nevertheless, current ELISA meth-
ods seem to have limitations in assessing HMGB1 levels
as a surrogate marker of active disease in different sce-
narios due to potential interference in its detection by
serum factors, including anti-HMGB1 antibodies. Per-
haps only free HMGB1 could be detected by current
ELISA systems instead of total HMGB1 [24,25]. Further-
more, it is now known that functionality of HMGB1 is
affected by the redox state of its three cysteine residues
(C23, C45 and C106) and future methods to detect
HMGB1 should take this functional nuance into
account. The all-thiol form of HMGB1 has only chemo-
tactic activity while disulfide-bonded HMGB1 (between
C23 and C45) induces cytokine release through binding
of TLR-4. No cytokine-stimulating or chemotactic activ-
ity is found in the fully oxidized HMGB1 [26,27].
We observed that AAV patients with renal involve-
ment presented similar HMGB1 levels in comparison
with HC while AAV patients without active nephritis
had significantly higher HMGB1 levels than HC. We
therefore speculate that the reason for finding serum
HMGB1 levels in AAV patients at presentation similar
to HC, in contrast to other studies evaluating HMGB1
Table 2 Longitudinal analysis of HMGB1 levels in patients with antineutrophil cytoplasmic antibodies-associated
vasculitis
Variable Presentation Early
remissiona
Ongoing
remission
Prior to
relapse 1
Relapse 1 Prior to
relapse 2
Relapse 2
HMGB1 (ng/ml) 2.35 (1.48 to
3.15)
1.69* (0.88 to
2.73)
2.21 (1.42 to 3.68) 2.59 (1.61 to
4.09)
2.56 (0.87 to
4.48)
3.65 (1.71 to
4.56)
2.77 (0.91 to
4.86)
Follow-up period
(months)
0 3.0b (3.0 to 6.0) 11.0b (6.0 to 12.0) 2.0c (2.0 to 3.0) 20.0b (13.0 to
41.5)
2.0c (1.0 to 2.0) 44.0b (35.2 to
68.5)
BVAS 15.0 (12.0 to
23.5)
0 0 0 12.0 (5.5 to 13.5) 0 11.0 (5.7 to 15.7)
Number of
patients
52 49 49 15 17 5 6
Data presented as median (interquartile range). BVAS, Birmingham Vasculitis Activity Score; HMGB1, high-mobility group box 1. aEarly remission indicates when
remission was achieved following induction treatment. bMonths after presentation. cMonths prior to the relapse. *Significant P value for fluctuation in HMGB1
levels between presentation and early remission.
Figure 4 Comparison of HMGB1 levels during follow-up in relapsing and nonrelapsing AAV patients. Using a generalized estimating
equation model, no significant differences were found between relapsing (n = 17) and nonrelapsing (n = 32) antineutrophil cytoplasmic
antibodies-associated vasculitis (AAV) patients regarding longitudinal levels of high-mobility group box 1 (HMGB1) (P = 0.350).
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in AAV [15,17], could be the high number of patients
with active renal involvement evaluated in the present
study (75.0%). Although Bruchfeld and colleagues have
previously described higher serum HMGB1 levels in
AAV patients with biopsy-proven active nephritis in
comparison with patients without active renal inflamma-
tion, no systematic comparison was made with AAV
patients presenting active disease in other organs or sys-
tems [16]. In line with our results, Henes and colleagues
described lower serum HMGB1 levels in GPA patients
with predominantly vasculitic manifestations when com-
pared with those with predominantly granulomatous
manifestations. Active nephritis was the most frequent
feature observed among GPA patients with vasculitic
manifestations. Granulomatous inflammation may have
contributed to higher HMGB1 levels in GPA patients
with granulomatous manifestations [17]. In our study,
patients with GPA and localized disease presented
higher levels of HMGB1 at baseline than patients with
generalized disease. Also, AAV patients with pulmonary
nodules and/or lung infiltrates had higher levels of
HMGB1 than those with alveolar hemorrhage. Differ-
ences, however, were not significant in both situations.
Nonetheless, the presence of granulomatous manife-
stations in AAV patients did not seem to influence
HMGB1 levels in AAV patients with simultaneously
active nephritis, indicating that HMGB1 levels were
mostly influenced by renal involvement. The increased
expression of HMGB1 in renal tissue [16] and the
necrotizing nature of glomerulonephritis in AAV indi-
cate that both active release by activated cells and pas-
sive release by dying necrotic cells could be the source
of extracellular HMGB1 in renal involvement of AAV
besides systemic inflammation. However, whether leak-
age of HMGB1 into urine due to renal damage contri-
butes to lower serum HMGB1 levels in parallel with
increased urinary levels of HMGB1 in active glomerulo-
nephritis in AAV is still unknown.
Serum HMGB1 levels have been correlated with dis-
ease activity in AAV in cross-sectional studies. Never-
theless, longitudinal evaluation of serum HMGB1 levels
demonstrated only a significant decrease in HMGB1
levels approximately 3 months after presentation. There-
after, with ongoing remission, serum HMGB1 returned
to levels similar to those found at presentation. Serum
HMGB1 levels prior to relapses and during relapses
were somewhat higher than baseline levels but this dif-
ference was not significant. Achievement of disease
remission in response to sustained immunosuppressive
therapy may be the reason for lower HMGB1 levels
within 3 months after disease presentation. Although
approximately one-half of AAV patients at presentation
were already under immunosuppressive therapy for a
median 3 weeks and no difference in serum HMGB1
levels could be found between patients with and without
therapy, both treated patients and untreated patients
had a similar median BVAS at baseline evaluation. After
achieving remission most AAV patients were still on
oral prednisolone and cyclophosphamide, whereas dur-
ing ongoing remission immunosuppressive therapy was
tapered and cyclophosphamide was changed to
azathioprine. Prior to relapses in the majority of AAV
patients, immunosuppressive therapy was withdrawn
(data not shown). This reduction in immunosuppressive
therapy may therefore account for the significant
increase in serum HMGB1 levels from early remission
to ongoing remission.
In this study, no difference regarding serum HMGB1
levels could be found during follow-up between relap-
sing and nonrelapsing AAV patients and fluctuations of
serum HMGB1 levels during the remission period or
prior to a relapse were not associated with an increased
risk of relapses in AAV. Hence, fluctuations of serum
HMGB1 levels cannot be used as a surrogate marker for
disease activity in AAV.
Conclusions
Nonrenal AAV is associated with higher serum HMGB1
levels at presentation and serum HMGB1 levels decrease
significantly within 3 months after presentation, possibly
due to immunosuppressive treatment, but during
ongoing remission HMGB1 levels return to levels simi-
lar to those observed at presentation. A slight nonsigni-
ficant increase in HMGB1 levels is observed prior to
Table 3 HMGB1 levels as a biomarker of relapse risk in antineutrophil cytoplasmic antibodies-associated vasculitis
patients
HMGB1 levels Hazard rate 95% confidence interval P value
At baseline 0.812 0.529 to 1.248 0.327
At early remissiona 0.963 0.641 to 1.446 0.854
At ongoing remission 1.344 0.746 to 2.420 0.325
Prior to relapse 1 0.967 0.776 to 1.205 0.762
Delta between early remission and prior to relapse 1 0.959 0.751 to 1.226 0.739
Delta between ongoing remission and prior to relapse 1 0.919 0.728 to 1.161 0.478
Cox hazard proportional model to evaluate the role of HMGB1 levels as a biomarker of relapse risk in antineutrophil cytoplasmic antibodies-associated vasculitis
patients. HMGB1, high-mobility group box 1. aEarly remission indicates when remission was achieved.
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and during relapses in comparison with baseline levels.
No association between fluctuations of serum HMGB1
levels and risk of relapse could be found. Circulating
HMGB1 measured by ELISA therefore does not seem
to be a useful biomarker of disease activity in AAV.
Patients with AAV did not develop significant anti-
HMGB1 antibodies during active disease.
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